Sign in
BMRN Stock Price, Chart, Stats & News
BioMarin Pharmaceutical Inc.
Save
BioMarin Pharmaceutical Inc. (BMRN) does not currently pay a dividend.
10.58B
Market cap
26.28x
Current P/E
9.40x
Forward P/E
BMRN chart
Fundamentals
Gross margin | 77.13% |
Operating margin | 16.56% |
Pretax margin | 14.98% |
Net margin | 10.83% |
Effective tax rate | 27.69% |
ROA | 4.59% |
ROE | 5.82% |
D/E | 0.11x |
Interest coverage ratio | 48.95x |
BMRN valuation
P/E | 26.28x |
P/S | 3.23x |
P/B | 1.71x |
P/CF | 12.54x |
P/FCF | 14.36x |
P/OCF | 12.54x |
PEG | -0.90x |
EV multiple | 19.34x |
About
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI.
Similar securities
Based on sector and market capitalization
Report issue